Copertina

Number of Prescription Medications and Overall Survival in Metastatic Castrate‐Resistant Prostate Cancer

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Carley R. Pickett, Daniel B. Eaton, Krishny Karunanandaa, Emily Cybulla, Brendan T. Heiden, Su-Hsin Chang, Yan Yan, Melanie P. Subramanian, Varun Puri, Martin W. Schoen
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Prostate Cancer
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Association of Weight Loss and BMI on PSA Levels and Overall Survival in Veterans With Metastatic Castrate‐Resistant Prostate Cancer
di: Nicholas Fedele, et al.
Pubblicazione: (2025)

Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer
di: András Horváth, et al.
Pubblicazione: (2025)

Directed Evolution Restored Castrate Sensitivity in a Patient With Castrate Resistant Metastatic Prostate Cancer
di: Robert A. Gatenby, et al.
Pubblicazione: (2025)

Castration Resistance Accelerates Prostate Cancer Kinetics
di: Sheila Jonnatan, et al.
Pubblicazione: (2026)

Outcome of Subsequent Therapies After 177Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience
di: Meryam Losee, et al.
Pubblicazione: (2025)

Comments on the Study “Adapting the Bellmunt Risk Score for Prognostic Stratification in Metastatic Castration‐Sensitive Prostate Cancer”
di: Xian Wen
Pubblicazione: (2026)

Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration‐Resistant Prostate Cancer: A Real‐World Multi‐Intuitional Analysis
di: Kotaro Suzuki, et al.
Pubblicazione: (2025)

Baseline Imaging Derived Factors of Response Following [225Ac]Ac‐J591 Therapy in Metastatic Castration‐Resistant Prostate Cancer: A Lesion Level Analysis
di: Judith Stangl‐Kremser, et al.
Pubblicazione: (2025)

Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate
di: Mitsuhisa Nishimoto, et al.
Pubblicazione: (2025)

Establishment and Characterization of Patient‐Derived Xenograft Organoids for Personalized Treatment of Castration‐Resistant Prostate Cancer
di: Takuro Sunada, et al.
Pubblicazione: (2026)

Restoration of Mitochondrial Function: A Metabolic Perspective on “Directed Evolution” in Castration‐Resistant Prostate Cancer
di: Po‐Jung Su, et al.
Pubblicazione: (2026)

Efficacy, Safety, and Cost‐Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer: A Multicenter Retrospective Study
di: Himawari Asanuma, et al.
Pubblicazione: (2026)

Real‐World Treatment Patterns Before and After Metastatic Castration–Resistant Prostate Cancer in Japan: Retrospective Analysis Using a Hospital‐Based, Multicenter Database
di: Masaki Shiota, et al.
Pubblicazione: (2026)

Impact of the Nadir Androgen Receptor Signaling Inhibitor‐Derived Integrative Response Model in Real‐World Patients With Metastatic Castration‐Sensitive Prostate Cancer
di: Kazuma Yukihiro, et al.
Pubblicazione: (2026)

Towards Precision Oncology: A New Predictive Machine Learning Model for Early Progression to Castration Resistant Prostate Cancer
di: Miguel Ángel Gómez‐Luque, et al.
Pubblicazione: (2025)

Comparative Effectiveness of First‐Line Treatments for Castration‐Resistant Prostate Cancer: A Large‐Scale Retrospective Study in Japan
di: Akihito Hashizume, et al.
Pubblicazione: (2025)

Comprehensive Genomic Profiling Testing for Castration‐Resistant Prostate Cancer in Advanced Elderly Patients: A Single‐Center Retrospective Cohort Study
di: Takafumi Fukushima, et al.
Pubblicazione: (2025)

A Phase II, Single Arm, Multicentre Trial of Triamcinolone With a GnRH Analog for Castrate‐Resistant Prostate Cancer (TRICREST)
di: Kenrick Ng, et al.
Pubblicazione: (2025)

Prognostic Nutritional Index as a Biomarker in Metastatic Hormone‐Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization
di: Muhammet Bekir Hacioglu, et al.
Pubblicazione: (2025)

Evaluation of Second‐Line Treatment for Castration‐Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors
di: Kazuro Kikkawa, et al.
Pubblicazione: (2024)

Downregulation of NONO Suppresses Proliferation, Migration, and Invasion in Metastatic Prostate Cancer
di: Anna‐Lena Lemster, et al.
Pubblicazione: (2025)

Prostate‐Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone‐Sensitive Prostate Cancer Treated With Apalutamide
di: Christian Andrés Martínez Osorio, et al.
Pubblicazione: (2025)

Genetics‐Driven, Intensity‐Modulated Adaptive Management of Patients With Metastatic Prostate Cancer
di: Reynier D. Rodriguez Rosales, et al.
Pubblicazione: (2025)

Corticosteroid Use and Risk of Adverse Events in Metastatic Hormone‐Sensitive Prostate Cancer
di: Umang Swami, et al.
Pubblicazione: (2026)

Clinicopathological Significance of Extranodal Adipose Tissue Invasion in Metastatic Lymph Nodes in Patients With Prostate Cancer
di: Hirotaka Nagasaka, et al.
Pubblicazione: (2024)

Effect of Marital Status on Years of Life Lost From Metastatic Prostate Cancer According to Race/Ethnicity
di: Leonardo Quarta, et al.
Pubblicazione: (2026)

A Two‐Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone‐Sensitive Prostate Cancer
di: Koichiro Kurokawa, et al.
Pubblicazione: (2026)

Bone Metastasis Distribution Matters: Prognostic Effect of the Axial‐to‐Peripheral Ratio in Metastatic Hormone‐Sensitive Prostate Cancer
di: Ali Fuat Gürbüz, et al.
Pubblicazione: (2026)

Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer
di: Eva Streckova, et al.
Pubblicazione: (2025)

Survival Outcomes for Rural Patients With Advanced Prostate Cancer: A SEER Investigation
di: Liang G. Qu, et al.
Pubblicazione: (2025)

The Clinical Significance of Gallium‐68 PSMA‐11 PET‐Derived SUVmax in the Management of Metastatic Hormone‐Sensitive Prostate Cancer
di: Cevat İlteriş Kıkılı, et al.
Pubblicazione: (2026)

Effects of Concurrent Administration of Spironolactone in Veterans with Metastatic Prostate Cancer Receiving Abiraterone: A Real‐World Retrospective Study
di: Erum Z. Whyne, et al.
Pubblicazione: (2024)

Prognostic Impact of Initial Prostate Specific Antigen Half‐Life After Abiraterone Acetate in High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: Who May Need Triplet Therapy?
di: Kotaro Suzuki, et al.
Pubblicazione: (2026)

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy
di: Takeshi Tsutsumi, et al.
Pubblicazione: (2026)

Overall and metastasis‐free survival of Afro‐Caribbean patients with biochemical recurrence after radical prostatectomy
di: Hugo Barriere, et al.
Pubblicazione: (2024)

Prostate Specific Antigen Density and Clinically‐Significant Prostate Cancer: The Influence of Prostatic Volume
di: Elizabeth Robinson, et al.
Pubblicazione: (2025)

Probenecid and Eugenol Mitigate Testosterone Induced Benign Prostatic Hyperplasia by Targeting Uric Acid‐Induced Inflammation and Pro‐Survival Pathways
di: Nibrass Taher Abdali, et al.
Pubblicazione: (2025)

Progression‐Free Survival Prediction Performance of ChatGPT: Analysis With Real Life Data in Early and Locally Advanced Prostate Cancer
di: Engin Eren Kavak, et al.
Pubblicazione: (2025)

Deciphering Resistance: Beyond the Androgen Paradigm; Report From the 2025 Coffey‐Holden Prostate Cancer Academy Meeting
di: Tanya Stoyanova, et al.
Pubblicazione: (2025)

Refining the CHAARTED Classification: Clinical Utility of a Novel Integrated Risk Stratification Model Incorporating Gleason Grade and Biochemical Markers in Japanese Patients With Metastatic Hormone‐Sensitive Prostate Cancer
di: Takanori Tokunaga, et al.
Pubblicazione: (2025)